MedTrace Logo

MATERNAL AND NEONATAL SCREENING FOR GROUP B STREPTOCOCCI : A Follow up STUDY

NCT04227730 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2022-03-31

No results posted yet for this study

Summary

Group B Streptococcus (GBS), is a facultative gram positive diplococcus originally known for causing bovine mastitis and was not demonstrated to be a human pathogen until 1938. In the 1970s, GBS emerged as the leading cause of neonatal morbidity and mortality, with a frequency of 2-3 cases per 1,000 live births and case-fatality ratios as high as 50%

Conditions

  • Group B Streptococcal Infection

Interventions

DIAGNOSTIC_TEST

culture and PCR for group B streptococcus

all participants were evaluated by vaginorectal specimens for the detection of GBS, The swabs are placed in Amies transport medium and sent to the microbiology laboratory for testing by conventional PCR assay.

Sponsors & Collaborators

  • Fayoum University Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
46 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-01
Primary Completion
2020-12-30
Completion
2020-12-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04227730 on ClinicalTrials.gov